2013/01 - Galactosaminogalactan comprising alpha 1-4 linked galactose and alpha 1-4 linked N-acetylgalactosamine for use in the treatment of at least one inflammatory disease
- Titolo brevetto
- Galactosaminogalactan comprising alpha 1-4 linked galactose and alpha 1-4 linked N-acetylgalactosamine for use in the treatment of at least one inflammatory disease
- Stato
- Abbandonato
- Numero domanda di priorità
- EP 13305034.4 - a nome dell'Institut Pasteur
- Data di priorità
- 2013-01-14 00:00:00
- Fase
- EUROPA, esteso a PCT
- Dipartimento
- Dipartimento di medicina sperimentale
- Autori
- Luigina Romani, Antonella De Luca, Silvia Bozza, Jean Paul Latgé; Thierry Fontaine, F. van de Veerdonck, L. Joosten, M. Gresnigt, M. Netea
- Co-titolari
- INSTITUT PASTEUR (46%) - Università degli Studi di Perugia (25%) - RADBOUD UNIVERSITY NIJMEGEN (29%)
- Descrizione
A first object of the invention is galactosaminogalactan comprising [alpha]1-4 linked galactose, [alpha]1-4 linked N-acetylgalactosamine, and optionally [alpha]1-4 linked galactosamine, for use in the treatment of at least one inflammatory disease. Another object of the invention is a pharmaceutical composition comprising a galactosaminogalactan comprising [alpha]1-4 linked galactose, [alpha]1-4 linked N-acetylgalactosamine, and optionally [alpha]1-4 linked galactosamine, as defined herein, and optionally a pharmaceutically acceptable carrier. Another object of the invention is a pharmaceutical composition according to the invention, for use in the treatment of at least one inflammatory disease. Another object of the invention is an inhibitor of IL-1RA for use in the treatment of human fungal diseases. Another object of the invention is a pharmaceutical composition comprising an inhibitor of IL-1RA, and optionally a pharmaceutically acceptable carrier.
- Contatto
- ufficio.ilo@unipg.it